Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates
prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to …

Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of
cancer related death in men in Western countries. The standard therapy for metastatic PCa …

Purpose: The summary presented herein represents Part II of the two-part series dedicated
to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the
treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic …

Introduction Therapeutic options for metastatic castration-resistant prostate cancer (mCRPC)
patients are continuously advancing. We described mCRPC treatment patterns in the US …

Purpose: The advanced prostate cancer therapeutic landscape has changed dramatically in
the last several years, resulting in improved overall survival of patients with castration naïve …

The nuclear receptor superfamily comprises a large group of proteins with functions
essential for cell signaling, survival, and proliferation. There are multiple distinctions …

Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average
survival of only 13 months. Identification of novel predictive and actionable biomarkers in the …

The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an
increasing emergence of AR-independent castration-resistant prostate cancer (CRPC) …